Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
about
The RNA polymerase "switch region" is a target for inhibitorsMurine leukemia virus reverse transcriptase: structural comparison with HIV-1 reverse transcriptaseElucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulationsComputational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsAnchored plasticity opens doors for selective inhibitor design in nitric oxide synthaseHIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanismIn vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIsA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityBiochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA PolymeraseInsight into the structure, dynamics and the unfolding property of amylosucrases: implications of rational engineering on thermostabilityGlobal Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors.Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature.A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.HIV-1 antiretroviral drug therapy.Identifying representative drug resistant mutants of HIV.Investigational reverse transcriptase inhibitors for the treatment of HIV.Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analysesMolecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptaseAlizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases.Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).From base pair to bedside: molecular simulation and the translation of genomics to personalized medicine.Molecular Modeling, Synthesis, and Anti-HIV Activity of Novel Isoindolinedione Analogues as Potent Non-nucleoside Reverse Transcriptase Inhibitors.NMR structure of the HIV-1 reverse transcriptase thumb subdomain.Novel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational PatternA novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.Structural and energetic properties of the potential HIV-1 reverse transcriptase inhibitors d4A and d4G: a comprehensive theoretical investigation.HIV reverse transcriptase: structural interpretation of drug resistant genetic variants from India.The disposition and metabolism of GW695634: a non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS.Protein promiscuity: drug resistance and native functions--HIV-1 case.Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.Effects of crystalline state and self-nanoemulsifying drug delivery system (SNEDDS) on oral bioavailability of the novel anti-HIV compound 6-benzyl-1-benzyloxymethyl-5-iodouracil in rats.Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.Development of peptide inhibitors of HIV transmission.
P2860
Q24643039-132319AD-6A64-4B30-BE5E-747A25F886CAQ24647519-E3696EF1-77A3-4E71-A6D0-861741E97794Q24654012-1EED2783-8D78-4374-90CA-72D1936560DCQ26777448-A605B197-85D2-4AF7-8F8A-961794DFAAE6Q27652490-456A1CDB-0051-4B73-9549-CCAE9EB2D82FQ27676835-B5444375-9F60-4929-ADF6-38C9CB37EF56Q28391094-65430F19-8AFE-4E6B-BC4C-1242EDA56039Q28533996-B5143369-B529-4FB1-AB23-F82C2FAFE544Q28551925-102FB043-F16E-4699-A186-4E36BBB1CAB9Q28727426-220FFD04-C2F9-498E-AB68-03F7EFA738BDQ33565179-AB0FE2FB-32F4-4324-A339-37543F09CE0DQ33624190-C269844D-5BED-495F-A663-74C887350A29Q33649797-F0E981F4-C842-4EF3-8460-6E2B51645B65Q33682067-588340D6-B17B-4539-93C7-9E95A0D3CA18Q33826904-C46E6978-C821-4D5E-BE60-2E2A9A57E1D1Q33889635-A71F3403-58EC-43D6-B323-58F32A37C229Q35851936-50903A3F-695A-4E3C-ADC5-13A0765896A7Q35853012-33F447DF-7DC9-4647-B115-7E08DA5BD934Q35871681-79CE9BEB-BB18-4CB4-87FB-6437F359FF96Q36306231-C9A8F930-A6D4-458E-B750-6BE6B4A0D9C2Q36388297-4EA27F9C-1A3C-4285-8E96-C1DBB165058FQ36397384-359FF955-BE3F-4849-A481-847134938457Q36928605-BCBE72EF-FDF4-4A3B-BD90-47FAB971A70FQ36939750-4EB7202C-9431-49B6-A9C8-F3E3A737B1EBQ37860335-534CCB85-075E-43E6-845E-1C786FBF5C8EQ38035239-715B0B92-5C12-486B-98CB-CA5DADAEB237Q38849145-27C62D80-B898-4426-8FA2-751436179386Q39178488-0B8AB36F-4E23-4FAB-B4B4-43A363DEA0DCQ39627546-32A126C9-C881-4281-BA11-819E505B40BEQ39627553-017E403E-B070-4FFF-9A70-A0DFCED0B62DQ41879018-938FFE71-ADC3-4F2D-A4D5-0C5E1267A825Q42276579-008D6631-C248-4EAF-88AA-54A8BF26DF09Q42601729-97995448-91A4-4036-9C1F-DE518B63ECADQ43104680-4C98FEA5-70BC-4BDD-A224-D1D998218D56Q46074569-F7F3565E-B25B-4EAD-A08F-A35A6CEDEA01Q46230871-D31561CE-A95D-4D9F-96B7-9F00AFF0937EQ48608254-5A8A76CD-55A4-42F8-AF45-ADCC7C987D5BQ54549089-8138548D-11DF-40A3-AE23-ED7506E5DBC3Q55317261-B40346F2-5E89-426D-9D33-F0996F515082
P2860
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@ast
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@en
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@nl
type
label
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@ast
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@en
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@nl
prefLabel
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@ast
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@en
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@nl
P2860
P356
P1433
P1476
Conformational changes in HIV- ...... anscriptase inhibitor binding.
@en
P2093
N Alpay Temiz
Nicolas Sluis-Cremer
P2860
P304
P356
10.2174/1570162043351093
P50
P577
2004-10-01T00:00:00Z